Adjuvant Maintenance Larotrectinib Therapy in 2 Children With NTRK Fusion-positive High-grade Cancers.

Autor: Carter-Febres M; Division of Pediatric Hematology-Oncology., Schneller N; Division of Pediatric Hematology-Oncology., Fair D; Division of Pediatric Hematology-Oncology., Solomon D; Department of Pathology, University of California San Francisco, CA., Perry A; Department of Pathology, University of California San Francisco, CA., Roy A; Department of Pathology, Baylor College of Medicine, Texas Children's Hospital, Houston, TX., Linscott L; Medical Imaging., Alashari M; Departments of Pediatric Pathology., Kestle JR; Pediatric Neurosurgery, University of Utah School of Medicine and Primary Children's Hospital, Salt Lake City, UT., Bruggers CS; Division of Pediatric Hematology-Oncology.
Jazyk: angličtina
Zdroj: Journal of pediatric hematology/oncology [J Pediatr Hematol Oncol] 2021 Oct 01; Vol. 43 (7), pp. e987-e990.
DOI: 10.1097/MPH.0000000000001983
Abstrakt: Treatment-related morbidity drives research to identify targetable lesions in children with cancer. Neurotrophic tropomyosin receptor kinase (NTRK) alterations occur in ~1% of pediatric solid tumors. Early phase pediatric trials involving the NTRK inhibitor treatment for progressive NTRK-mutated cancers show promising results. The authors describe the adjuvant maintenance larotrectinib treatment after definitive surgical resection in 2 toddlers with NTRK fusion-positive malignancies (ETV6-NTRK3 fusion-positive undifferentiated embryonal sarcoma of the kidney and NACC2-NTRK2 fusion-positive anaplastic astrocytoma). Both are alive, in remission, developing normally and tolerating larotrectinib 15 months later, thus extending the NTRK inhibitor therapeutic spectrum by describing the adjuvant maintenance larotrectinib treatment in children with NTRK fusion-positive cancers associated with high recurrences.
Competing Interests: The authors declare no conflict of interest.
(Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze: MEDLINE